423 related articles for article (PubMed ID: 21296237)
1. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial.
Pelsser LM; Frankena K; Toorman J; Savelkoul HF; Dubois AE; Pereira RR; Haagen TA; Rommelse NN; Buitelaar JK
Lancet; 2011 Feb; 377(9764):494-503. PubMed ID: 21296237
[TBL] [Abstract][Full Text] [Related]
2. [Favourable effect of a standard elimination diet on the behavior of young children with attention deficit hyperactivity disorder (ADHD): a pilot study].
Pelsser LM; Buitelaar JK
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2543-7. PubMed ID: 12532668
[TBL] [Abstract][Full Text] [Related]
3. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
Boellner SW; Earl CQ; Arora S
Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
[TBL] [Abstract][Full Text] [Related]
4. Neurofeedback, sham neurofeedback, and cognitive-behavioural group therapy in adults with attention-deficit hyperactivity disorder: a triple-blind, randomised, controlled trial.
Schönenberg M; Wiedemann E; Schneidt A; Scheeff J; Logemann A; Keune PM; Hautzinger M
Lancet Psychiatry; 2017 Sep; 4(9):673-684. PubMed ID: 28803030
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial into the effects of food on ADHD.
Pelsser LM; Frankena K; Toorman J; Savelkoul HF; Pereira RR; Buitelaar JK
Eur Child Adolesc Psychiatry; 2009 Jan; 18(1):12-9. PubMed ID: 18431534
[TBL] [Abstract][Full Text] [Related]
9. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial.
Hiscock H; Sciberras E; Mensah F; Gerner B; Efron D; Khano S; Oberklaid F
BMJ; 2015 Jan; 350():h68. PubMed ID: 25646809
[TBL] [Abstract][Full Text] [Related]
10. Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial.
Kefalopoulou Z; Zrinzo L; Jahanshahi M; Candelario J; Milabo C; Beigi M; Akram H; Hyam J; Clayton J; Kass-Iliyya L; Silverdale M; Evans J; Limousin P; Hariz M; Joyce E; Foltynie T
Lancet Neurol; 2015 Jun; 14(6):595-605. PubMed ID: 25882029
[TBL] [Abstract][Full Text] [Related]
11. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
Ngandu T; Lehtisalo J; Solomon A; Levälahti E; Ahtiluoto S; Antikainen R; Bäckman L; Hänninen T; Jula A; Laatikainen T; Lindström J; Mangialasche F; Paajanen T; Pajala S; Peltonen M; Rauramaa R; Stigsdotter-Neely A; Strandberg T; Tuomilehto J; Soininen H; Kivipelto M
Lancet; 2015 Jun; 385(9984):2255-63. PubMed ID: 25771249
[TBL] [Abstract][Full Text] [Related]
12. Foods and additives are common causes of the attention deficit hyperactive disorder in children.
Boris M; Mandel FS
Ann Allergy; 1994 May; 72(5):462-8. PubMed ID: 8179235
[TBL] [Abstract][Full Text] [Related]
13. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
[TBL] [Abstract][Full Text] [Related]
14. Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Bishop N; Adami S; Ahmed SF; Antón J; Arundel P; Burren CP; Devogelaer JP; Hangartner T; Hosszú E; Lane JM; Lorenc R; Mäkitie O; Munns CF; Paredes A; Pavlov H; Plotkin H; Raggio CL; Reyes ML; Schoenau E; Semler O; Sillence DO; Steiner RD
Lancet; 2013 Oct; 382(9902):1424-32. PubMed ID: 23927913
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
16. Individual Behavioral Reactions in the Context of Food Sensitivities in Children with Attention-Deficit/Hyperactivity Disorder before and after an Oligoantigenic Diet.
Yorgidis E; Beiner L; Blazynski N; Schneider-Momm K; Clement HW; Rauh R; Schulz E; Clement C; Fleischhaker C
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444758
[TBL] [Abstract][Full Text] [Related]
17. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial.
Frei H; Everts R; von Ammon K; Kaufmann F; Walther D; Hsu-Schmitz SF; Collenberg M; Fuhrer K; Hassink R; Steinlin M; Thurneysen A
Eur J Pediatr; 2005 Dec; 164(12):758-67. PubMed ID: 16047154
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
[TBL] [Abstract][Full Text] [Related]
19. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder.
Montoya A; Hervas A; Cardo E; Artigas J; Mardomingo MJ; Alda JA; Gastaminza X; García-Polavieja MJ; Gilaberte I; Escobar R
Curr Med Res Opin; 2009 Nov; 25(11):2745-54. PubMed ID: 19785510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
